|
EP4373822A2
(en)
|
2021-07-23 |
2024-05-29 |
Theras Inc. |
Compositions and methods for inhibition of ras
|
|
TW202328124A
(zh)
*
|
2021-08-18 |
2023-07-16 |
大陸商北京加科思新藥研發有限公司 |
1,4-氧雜氮雜環庚烷衍生物及其用途
|
|
JP2024543879A
(ja)
*
|
2021-11-24 |
2024-11-26 |
メルク・シャープ・アンド・ドーム・エルエルシー |
Ｋｒａｓ変異型タンパク質の小分子阻害剤
|
|
AU2023218370B2
(en)
|
2022-02-09 |
2024-11-28 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
CN119585287A
(zh)
|
2022-05-06 |
2025-03-07 |
Paq医疗公司 |
Kras g12d蛋白水解靶向嵌合体
|
|
IL317601A
(en)
|
2022-05-25 |
2025-02-01 |
Quanta Therapeutics Inc |
Pyrimidine-based modulators and their uses
|
|
WO2024046370A1
(zh)
*
|
2022-08-30 |
2024-03-07 |
上海科州药物研发有限公司 |
作为kras抑制剂的杂环化合物，及其制备和治疗用途
|
|
CN117659050A
(zh)
*
|
2022-09-08 |
2024-03-08 |
深圳福沃药业有限公司 |
用于治疗癌症的kras突变抑制剂的喹唑啉杂环类衍生物
|
|
WO2024112654A1
(en)
|
2022-11-21 |
2024-05-30 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
WO2024125600A1
(zh)
*
|
2022-12-14 |
2024-06-20 |
上海科州药物研发有限公司 |
作为kras抑制剂的杂环化合物，及其制备和治疗用途
|
|
WO2024192424A1
(en)
|
2023-03-15 |
2024-09-19 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
EP4687905A1
(en)
|
2023-03-30 |
2026-02-11 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
AU2024265078A1
(en)
|
2023-05-04 |
2025-12-11 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
WO2024235225A1
(zh)
*
|
2023-05-15 |
2024-11-21 |
苏州泽璟生物制药股份有限公司 |
取代嘧啶并环类抑制剂及其制备方法和应用
|
|
IL326136A
(en)
|
2023-08-07 |
2026-03-01 |
Revolution Medicines Inc |
RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
|
|
AU2024323424A1
(en)
|
2023-08-17 |
2026-03-05 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
AU2024337913A1
(en)
|
2023-09-08 |
2026-03-26 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
TW202528315A
(zh)
|
2023-09-21 |
2025-07-16 |
美商樹線生物科學公司 |
螺環二氫哌喃并吡啶ＫＲａｓ抑制劑
|
|
US12599672B2
(en)
|
2023-10-03 |
2026-04-14 |
PAQ Therapeutics Inc. |
KRAS proteolysis targeting chimeras
|
|
US20250154171A1
(en)
|
2023-10-12 |
2025-05-15 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025117828A1
(en)
*
|
2023-12-01 |
2025-06-05 |
Theras, Inc. |
Compositions and methods for inhibition of ras
|
|
WO2025145207A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg-depleting agent
|
|
WO2025148868A1
(zh)
*
|
2024-01-08 |
2025-07-17 |
泰励生物科技（上海）有限公司 |
一种抗体偶联药物及其用途
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202547457A
(zh)
*
|
2024-04-08 |
2025-12-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
二氫呋喃并[3,4-f]喹唑啉類化合物、其製備方法及其在醫藥上的應用
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025245105A1
(en)
*
|
2024-05-20 |
2025-11-27 |
Erasca, Inc. |
Kras inhibitors
|
|
WO2025245127A1
(en)
|
2024-05-21 |
2025-11-27 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026002172A1
(zh)
*
|
2024-06-26 |
2026-01-02 |
上海青润医药科技有限公司 |
Kras突变体抑制剂及其药物组合物、制备方法和应用
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026035945A1
(en)
|
2024-08-07 |
2026-02-12 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
|
|
WO2026035947A1
(en)
|
2024-08-07 |
2026-02-12 |
Tesseract Medicines Us, Llc |
Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload
|
|
WO2026039512A1
(en)
|
2024-08-14 |
2026-02-19 |
Bristol-Myers Squibb Company |
Kras inhibitors
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026064527A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
|
|
WO2026064520A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|